Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Obese and overweight patients with hepatitis B virus-related hepatocellular carcinoma (HCC) show improved outcomes when treated with lenvatinib and camrelizumab. Body mass index (BMI) is a key predictor of treatment efficacy and overall survival in these patients.
Area Of Science
- Hepatology
- Oncology
- Clinical Medicine
Background
- Primary liver cancer, predominantly hepatocellular carcinoma (HCC), has a poor prognosis despite available treatments.
- Identifying patient populations who benefit most from current therapies is crucial for improving outcomes.
- Hepatitis B virus (HBV) is a major risk factor for HCC globally.
Purpose Of The Study
- To assess the clinical effectiveness of combining lenvatinib with camrelizumab for HBV-related HCC.
- To evaluate the impact of body mass index (BMI) categories on treatment outcomes in Barcelona Clinic Liver Cancer (BCLC) stages B/C patients.
- To identify independent prognostic factors for overall survival (OS) in this patient cohort.
Main Methods
- Retrospective analysis of 126 HBV-related HCC patients treated with lenvatinib plus camrelizumab.
- Patients categorized into non-overweight (BMI < 25 kg/m²) and overweight/obese (BMI ≥ 25 kg/m²) groups.
- Prognosis evaluated using mRECIST criteria; Cox regression analysis identified prognostic factors for OS.
Main Results
- Obese/overweight patients demonstrated significantly longer progression-free survival and overall survival (OS) compared to non-overweight patients.
- Objective remission rates (28.00% vs 5.88%) and disease control rates (62.67% vs 39.22%) were higher in the overweight/obese group.
- Body mass index (BMI), BCLC grade, alpha-fetoprotein level, and portal vein tumor thrombosis were identified as independent prognostic factors for OS.
Conclusions
- Body mass index (BMI) is a significant long-term predictor of treatment efficacy for lenvatinib plus camrelizumab in HBV-related HCC.
- Obese and overweight patients exhibit a better prognosis and improved survival outcomes.
- The findings support personalized treatment strategies based on BMI in HCC management.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
